Cargando…

The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease

INTRODUCTION: This study investigated the diagnostic and disease‐monitoring potential of plasma biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) dementia and cognitively unimpaired (CU) individuals. METHODS: Plasma was analyzed using Simoa assays from 99 CU, 107 MCI, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simrén, Joel, Leuzy, Antoine, Karikari, Thomas K., Hye, Abdul, Benedet, Andréa Lessa, Lantero‐Rodriguez, Juan, Mattsson‐Carlgren, Niklas, Schöll, Michael, Mecocci, Patrizia, Vellas, Bruno, Tsolaki, Magda, Kloszewska, Iwona, Soininen, Hilkka, Lovestone, Simon, Aarsland, Dag, Hansson, Oskar, Rosa‐Neto, Pedro, Westman, Eric, Blennow, Kaj, Zetterberg, Henrik, Ashton, Nicholas J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Featured Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359457/ https://www.ncbi.nlm.nih.gov/pubmed/33491853 http://dx.doi.org/10.1002/alz.12283

Ejemplares similares

Stability of graph theoretical measures in structural brain networks in Alzheimer’s disease
por: Mårtensson, Gustav, et al.
Publicado: (2018)

Application of a MRI based index to longitudinal atrophy change in Alzheimer disease, mild cognitive impairment and healthy older individuals in the AddNeuroMed cohort
por: Aguilar, Carlos, et al.
Publicado: (2014)

The Effect of Age Correction on Multivariate Classification in Alzheimer’s Disease, with a Focus on the Characteristics of Incorrectly and Correctly Classified Subjects
por: Falahati, Farshad, et al.
Publicado: (2015)

Predicting Progression of Alzheimer’s Disease Using Ordinal Regression
por: Doyle, Orla M., et al.
Publicado: (2014)

Sensitivity and Specificity of Medial Temporal Lobe Visual Ratings and Multivariate Regional MRI Classification in Alzheimer's Disease
por: Westman, Eric, et al.
Publicado: (2011)

Automated Hippocampal Subfield Measures as Predictors of Conversion from Mild Cognitive Impairment to Alzheimer’s Disease in Two Independent Cohorts
por: Khan, Wasim, et al.
Publicado: (2014)

Random Forest ensembles for detection and prediction of Alzheimer's disease with a good between-cohort robustness()
por: Lebedev, A.V., et al.
Publicado: (2014)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration
por: Ashton, Nicholas J., et al.
Publicado: (2019)

Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum
por: Gobom, Johan, et al.
Publicado: (2022)

The accuracy and robustness of plasma biomarker models for amyloid PET positivity
por: Benedet, Andréa L., et al.
Publicado: (2022)

Plasma Biomarkers of Brain Atrophy in Alzheimer's Disease
por: Thambisetty, Madhav, et al.
Publicado: (2011)

Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2021)

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

Inflammatory Proteins in Plasma Are Associated with Severity of Alzheimer’s Disease
por: Leung, Rufina, et al.
Publicado: (2013)

A Pathway Based Classification Method for Analyzing Gene Expression for Alzheimer’s Disease Diagnosis
por: Voyle, Nicola, et al.
Publicado: (2015)

Differential Associations of IL-4 With Hippocampal Subfields in Mild Cognitive Impairment and Alzheimer’s Disease
por: Boccardi, Virginia, et al.
Publicado: (2019)

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
por: Cicognola, Claudia, et al.
Publicado: (2021)

Alzheimer's disease biomarker discovery using in silico literature mining and clinical validation
por: Greco, Ines, et al.
Publicado: (2012)

Disrupted Network Topology in Patients with Stable and Progressive Mild Cognitive Impairment and Alzheimer's Disease
por: Pereira, Joana B., et al.
Publicado: (2016)

Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline
por: Lantero Rodriguez, Juan, et al.
Publicado: (2020)

Plasma Based Markers of [(11)C] PiB-PET Brain Amyloid Burden
por: Kiddle, Steven John, et al.
Publicado: (2012)

Comparing progression biomarkers in clinical trials of early Alzheimer’s disease
por: Cullen, Nicholas C., et al.
Publicado: (2020)

Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy
por: Grothe, Michel J., et al.
Publicado: (2021)

Education increases reserve against Alzheimer’s disease—evidence from structural MRI analysis
por: Liu, Yawu, et al.
Publicado: (2012)

Effects of pre‐analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration
por: Ashton, Nicholas J., et al.
Publicado: (2021)

The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
por: Ashton, N. J., et al.
Publicado: (2021)

Genetic Predisposition to Increased Blood Cholesterol and Triglyceride Lipid Levels and Risk of Alzheimer Disease: A Mendelian Randomization Analysis
por: Proitsi, Petroula, et al.
Publicado: (2014)

Plasma biomarkers for Alzheimer’s Disease in relation to neuropathology and cognitive change
por: Smirnov, Denis S., et al.
Publicado: (2022)

Association between polygenic risk score of Alzheimer’s disease and plasma phosphorylated tau in individuals from the Alzheimer’s Disease Neuroimaging Initiative
por: Zettergren, Anna, et al.
Publicado: (2021)

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2021)

Deep Sequencing of the Nicastrin Gene in Pooled DNA, the Identification of Genetic Variants That Affect Risk of Alzheimer's Disease
por: Lupton, Michelle K., et al.
Publicado: (2011)

Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease
por: Moscoso, Alexis, et al.
Publicado: (2021)

Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum
por: Moscoso, Alexis, et al.
Publicado: (2020)

Differences between blood and cerebrospinal fluid glial fibrillary Acidic protein levels: The effect of sample stability
por: Simrén, Joel, et al.
Publicado: (2022)

Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition
por: Tideman, Pontus, et al.
Publicado: (2022)

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
por: Ossenkoppele, Rik, et al.
Publicado: (2021)

CERAD Neuropsychological Total Scores Reflect Cortical Thinning in Prodromal Alzheimer's Disease
por: Paajanen, T., et al.
Publicado: (2013)

Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates
por: Mulugeta, Ezra, et al.
Publicado: (2011)

Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer’s disease
por: Whiley, Luke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l39clhdcn4h9vurrcf3enl4t59